Longboard Pharmaceuticals Inc logo

Longboard Pharmaceuticals Inc Funding & Investors

Longboard Pharmaceuticals delivers medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. Its proprietary pipeline includes multiple programs with broad clinical utility. Longboard is evaluating LP352, a next-generation 5-HT2C agonist, in development for the potential treatment of developmental and epileptic encephalopathies, or DEEs. Longboard is also evaluating LP143, a centrally acting, full agonist of the cannabinoid type 2 receptor (CB2), and LP659, a centrally acting, next-generation, highly selective S1P receptor modulator.

longboardpharma.com

Total Amount Raised: $1,596,968

Longboard Pharmaceuticals Inc Funding Rounds

  • Post Ipo Equity

    $1,072,300

  • Post Ipo Debt

    $350,000

  • Post Ipo Debt

    $174,668

  • IPO

    Unknown

Funding info provided by Diffbot.